Arizona State University (ASU)

Arizona State University researchers awarded $4.7M by NIH to expand COVID-19 testing in underserved Arizona communities

Funding supports expansion of ASU’s COVID-19 services to the community

Newswise — Tempe, Ariz., October 1, 2020 – In Arizona, as in other parts of the country, data shows that COVID-19 has disproportionately affected the American Indian, African American and Latinx communities, as well as other vulnerable populations. A $4.7 million grant from the National Institute of Health to ASU’s Southwest Interdisciplinary Research Center (SIRC) is on the way to help address this by funding a rapid and large-scale increase in COVID-19 testing of underserved communities across Arizona.

“It is critical that all Americans have access to rapid, accurate diagnostics for COVID-19, especially underserved and vulnerable populations who are bearing the brunt of this disease,” said NIH Director Dr. Francis S. Collins. “The RADx-UP program will help us better understand and alleviate the barriers to testing for those most vulnerable and reduce the burden of this disease.”

ASU is one of 32 institutions receiving an NIH award through its Rapid Acceleration of Diagnostics (RADx) initiative, the RADx  Underserved Populations (RADx-UP) program.

In Arizona, the program aims to administer 29,000 saliva tests in minority communities throughout the state, as well as evaluate how well the intervention addresses COVID-19 testing-related barriers. ASU Biodesign Institute’s Clinical Testing Laboratory will provide saliva-based testing with a rapid turnaround for delivering test results.

The project begins immediately and is scheduled to run through June of 2022.

“SIRCs community-based effort has the promise of increasing access to testing and the preparation work for full participation in a future anticipated vaccine program,” said ASU President Michael Crow. “The evaluation component will enable us to document the intervention’s impact and to learn more about existing barriers and effective strategies needed to address the social determinants of health.”

The research team and its community partners hope to reduce the disparities in COVID-19 diagnostics, education and referral services — ultimately improving the health of underserved communities. The group’s approach is data driven and will empower local communities, meet community members where they are, and create the needed infrastructure for community-driven delivery of care.

"Receiving this supplemental award to our existing U54 center grant will allow us to significantly expand ASU’s COVID-19 related efforts in Arizona,” said Flavio Marsiglia, ASU Regents Professor who is also the Founder and Director of ASU’s Global Center for Applied Health Research (GCAHR) in Watts College of Public Service and Community Solutions. “The proposed project is the result of long- and well-established partnerships with the most vulnerable and underserved communities across the state and we look forward to working together with our community partners and an expanded transdisciplinary team of ASU investigators." 

The 18-month-long project brings together SIRC and GCAHR with a coalition of community-based organizations and their community health workers to implement an expanded and accessible COVID-19 testing program, identify and eliminate testing deserts, and provide services and referrals to people who test positive for the disease.

“This is an inspired, collaborative effort in the best tradition of SIRC, bringing together community members to address a gap in the service delivery system in a time of crisis,” said Jonathan Koppell, Dean of ASU’s Watts College of Public Service and Community Solutions. “There is important work to be done today and very important new knowledge will emerge from it.  Congratulations to Dr. Marsiglia and the entire transdisciplinary team, their community partners and to the entire SIRC and its Director Dr. Oesterle.”

SIRC is a research center at ASU whose mission is to generate use-inspired knowledge and interventions on social and cultural determinants of health in partnership with communities of the Southwest to prevent, reduce and eliminate health disparities. 

Community partners in the project include Equality Health Foundation, the Community and Scientific Advisory Board, COVID-19 Coalition of Communities of Color Partners, and ASU’s  Biodesign Institute Clinical Testing Laboratory and SIRC.

About ASU
Arizona State University has developed a new model for the American Research University, creating an institution that is committed to access, excellence and impact. ASU measures itself by those it includes, not by those it excludes. As the prototype for a New American University, ASU pursues research that contributes to the public good, and ASU assumes major responsibility for the economic, social and cultural vitality of the communities that surround it.




Filters close

Showing results

110 of 4146
Newswise: Long-Term Impacts of COVID-19: Your Mental Health
Released: 25-Nov-2020 2:15 PM EST
Long-Term Impacts of COVID-19: Your Mental Health
Cedars-Sinai

The COVID-19 pandemic has shaped more than half a year of our lives, canceling plans, upending livelihoods and causing feelings of grief, stress and anxiety. And Cedars-Sinai mental health experts say the pandemic could be shaping our mental health well into the future.

Released: 25-Nov-2020 12:45 PM EST
SARS-CoV-2 mutations do not appear to increase transmissibility
University College London

None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers.

Newswise: COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
Released: 25-Nov-2020 11:05 AM EST
COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
University of Alabama at Birmingham

Maryland-based Altimmune Inc., a clinical stage biopharmaceutical company, has submitted an Investigational New Drug, or IND, application to the United States Food and Drug Administration to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.

Released: 25-Nov-2020 11:05 AM EST
BIDMC researchers reveal how genetic variations are linked to COVID-19 disease severity
Beth Israel Lahey Health

New research BIDMC-led sheds light on the genetic risk factors that make individuals more or less susceptible to severe COVID-19.

Newswise: blog-pandemic-scenario-planning-lg-feature2.jpg
Released: 25-Nov-2020 11:05 AM EST
Pandemic Ups Game on Scenario Planning in The Arts
Wallace Foundation

Researcher/Author of new toolkit and report seeks to help arts and culture organizations add scenario planning to their strategic toolbox

Released: 25-Nov-2020 10:30 AM EST
Young people's anxiety levels doubled during first COVID-19 lockdown, says study
University of Bristol

The number of young people with anxiety doubled from 13 per cent to 24 per cent, during the early stages of the COVID-19 pandemic and lockdown 1, according to new research from the University of Bristol.

Newswise: 249837_web.jpg
Released: 25-Nov-2020 10:20 AM EST
Tracking COVID-19 trends in hard-hit states
Louisiana State University

Currently, there are over 10 million confirmed cases and more than 240,000 casualties attributed to COVID-19 in the U.S.

Released: 25-Nov-2020 9:55 AM EST
More Health Systems Join National #MaskUp Campaign
Cleveland Clinic

Many more health systems are joining the national #MaskUp campaign encouraging Americans to stop the spread of COVID-19 by following safety guidelines. Over just a few days, another 19 health systems with hundreds of hospitals united with 100 health systems nationwide with hospitals numbering in the thousands. The public service campaign is critical to the health and well-being of all Americans. It is a plea from healthcare professionals everywhere: wear a mask and follow other precautions to save lives and help get our country back on its feet.

Newswise: delaterre_jpeg.jpg
Released: 25-Nov-2020 7:35 AM EST
Warwick scientists design model to predict cellular drug targets against Covid-19
University of Warwick

The covid-19 virus, like all viruses relies on their host for reproduction

access_time Embargo lifts in 2 days
Embargo will expire: 30-Nov-2020 10:00 AM EST Released to reporters: 24-Nov-2020 5:35 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 30-Nov-2020 10:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.


Showing results

110 of 4146

close
2.37187